REACH| 30 SEPTEMBER 2021
ImmuPharma PLC
("ImmuPharma", the "Company" or the "Group")
PROF. SYLVIANE MULLER AWARDED PRESTIGIOUS
'LEGION D'HONNEUR'
ImmuPharma PLC (LSE:IMM; Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, is delighted to announce that Prof. Sylviane Muller, inventor of Lupuzor™ and P140 technology and a key collaboration partner, has been awarded the highly prestigious Legion d'honneur Award.
The 'Remise des insignes d'officier de la Légion d'honneur' was presented to Prof. Muller at an
awards ceremony yesterday evening at l'Institut de Science et d'Ingénierie Supramoléculaires (ISIS) in
The 'Legion of Honor' is the highest French decoration and one of the most famous in the world. For two centuries, being established in 1802 by Napoleon Bonaparte, it has been retained by all later French governments and presented on behalf of the Head of State to reward the most deserving citizens in all fields of activity.
Commenting on this award, Tim McCarthy, CEO and Chairman of ImmuPharma, said:
"On behalf of the Board and the whole team at ImmuPharma, we congratulate Prof. Muller on this highly prestigious award, which is highly deserving, in recognition of her many years of work and commitment to understanding the complexities of the human immune system. We are hugely honoured to be working in partnership with Prof. Muller on Lupuzor™ and the P140 platform, in which her passion and drive and collaborative approach has been an invaluable contribution to our clinical team, as we move closer to offering therapeutic drugs, initially in lupus, which will be of enormous benefit to patients."
End
|
For further information please contact:
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase 3 for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase 3 trial for Lupuzor™ and commercialise in the US.
For additional information about ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.
About Legion d'honneur
The Legion of Honor is the highest French decoration and one of the most famous in the world. For two centuries, being established in 1802 by Napoleon Bonaparte, it has been retained by all later French governments and presented on behalf of the Head of State to reward the most deserving citizens in all fields of activity.
The order's motto is Honneur et Patrie ("Honour and Fatherland"), and its seat is the Palais de la Légion d'Honneur next to the Musée d'Orsay, on the left bank of the Seine in
The order is divided into five degrees of increasing distinction: Chevalier (Knight), Officier (Officer), Commandeur (Commander), Grand officier (Grand Officer), and Grand-croix (Grand Cross). For more information go to: www.legiondhonneur.fr/en
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.